---
figid: PMC7237121__CMAR-12-3477-g0001
figlink: pmc/articles/PMC7237121/figure/F0001/
number: F1
caption: 'Mechanism of CDK4/6 inhibitors and possible combined therapy with CDK4/6
  inhibitors. Activation of upstream signaling pathways, such as MAPK, PI3K and ER,
  promotes the formation of cyclin D-CDK4/6 complex, which phosphorylates Rb protein.
  With phosphorylation of Rb, E2F is dissociated from Rb-E2F complex. As a transcription
  factor, released E2F initiates DNA synthesis, resulting in cell cycle progressed
  into S phase from G1 phase. CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib)
  prevent the activation of CDK4/6 to cause cell cycle arrest at G1 phase. Combination
  therapeutic strategies mainly focus on blockade of upstream of cyclin D-CDK4/6 signaling,
  including blockade of ER by AIs, fulvestrant and tamoxifen, blockade MAPK by BRAF
  inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (cobimetinib and trametinib),
  and blockade of PI3K pathway by alpelisib and everolimus.Abbreviations: CDK, cyclin-dependent
  kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase;
  ER, estrogen receptor; AI, aromatase inhibitor.'
pmcid: PMC7237121
papertitle: Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
reftext: Yanmei Wu, et al. Cancer Manag Res. 2020;12:3477-3487.
pmc_ranked_result_index: '1808'
pathway_score: 0.9562204
filename: CMAR-12-3477-g0001.jpg
figtitle: CDK4/6 inhibitors and possible combined therapy with CDK4/6 inhibitors
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7237121__CMAR-12-3477-g0001.html
  '@type': Dataset
  description: 'Mechanism of CDK4/6 inhibitors and possible combined therapy with
    CDK4/6 inhibitors. Activation of upstream signaling pathways, such as MAPK, PI3K
    and ER, promotes the formation of cyclin D-CDK4/6 complex, which phosphorylates
    Rb protein. With phosphorylation of Rb, E2F is dissociated from Rb-E2F complex.
    As a transcription factor, released E2F initiates DNA synthesis, resulting in
    cell cycle progressed into S phase from G1 phase. CDK4/6 inhibitors (palbociclib,
    ribociclib and abemaciclib) prevent the activation of CDK4/6 to cause cell cycle
    arrest at G1 phase. Combination therapeutic strategies mainly focus on blockade
    of upstream of cyclin D-CDK4/6 signaling, including blockade of ER by AIs, fulvestrant
    and tamoxifen, blockade MAPK by BRAF inhibitors (vemurafenib and dabrafenib) and
    MEK inhibitors (cobimetinib and trametinib), and blockade of PI3K pathway by alpelisib
    and everolimus.Abbreviations: CDK, cyclin-dependent kinase; MAPK, mitogen-activated
    protein kinase; PI3K, phosphoinositide 3-kinase; ER, estrogen receptor; AI, aromatase
    inhibitor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - HRAS
  - KRAS
  - NRAS
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - MAP2K1
  - MAP2K2
  - MTOR
  - MAPK3
  - MAPK1
  - IGFALS
  - CDK4
  - CDK6
  - E2F3
  - E2F8
  - E2F1
  - E2F2
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - Vemurafenib
  - Dabrafenib
  - Everolimus
  - Cobimetinib
  - Trametinib
  - Tamoxifen
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Als
  symbol: ALS
  source: hgnc_alias_symbol
  hgnc_symbol: IGFALS
  entrez: '3483'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
chemicals:
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Tamoxifen
  source: MESH
  identifier: D013629
diseases: []
figid_alias: PMC7237121__F1
redirect_from: /figures/PMC7237121__F1
figtype: Figure
---
